Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Share-based Compensation: 2012-2024

Historic Share-based Compensation for Rocket Pharmaceuticals (RCKT) over the last 13 years, with Dec 2024 value amounting to $43.9 million.

  • Rocket Pharmaceuticals' Share-based Compensation fell 13.24% to $9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.0 million, marking a year-over-year decrease of 1.70%. This contributed to the annual value of $43.9 million for FY2024, which is 11.46% up from last year.
  • Rocket Pharmaceuticals' Share-based Compensation amounted to $43.9 million in FY2024, which was up 11.46% from $39.4 million recorded in FY2023.
  • Rocket Pharmaceuticals' Share-based Compensation's 5-year high stood at $43.9 million during FY2024, with a 5-year trough of $18.6 million in FY2020.
  • Moreover, its 3-year median value for Share-based Compensation was $39.4 million (2023), whereas its average is $38.1 million.
  • Data for Rocket Pharmaceuticals' Share-based Compensation shows a peak YoY spiked of 57.47% (in 2021) over the last 5 years.
  • Rocket Pharmaceuticals' Share-based Compensation (Yearly) stood at $18.6 million in 2020, then skyrocketed by 57.47% to $29.2 million in 2021, then climbed by 6.06% to $31.0 million in 2022, then climbed by 27.08% to $39.4 million in 2023, then climbed by 11.46% to $43.9 million in 2024.